IDEAYA Biosciences Closes $323.6M Public Offering, Including Full Underwriter Option Exercise
IDYA sits 35% above its 52-week low of $20.5.
Summary
IDEAYA Biosciences announced the closing of its public offering, raising approximately $323.6 million in net proceeds, including the full exercise of the underwriters' option.
Key Events · Financing and Capital Events · IDYA
-
Public Offering Closed
The public offering of common stock and pre-funded warrants officially closed on June 10, 2026, finalizing the capital raise.
-
Significant Capital Raised
IDEAYA Biosciences received approximately $323.6 million in net proceeds from the offering, bolstering its financial runway.
-
Full Underwriter Option Exercise
The underwriters fully exercised their option to purchase an additional 1,666,669 shares of common stock, indicating strong investor demand for the offering.
-
Funding Clinical Development
The proceeds will be used to support the company's ongoing clinical development programs, building on recent positive trial data and strategic partnerships.
Analysis · IDYA · Life Sciences
This 8-K filing finalizes the previously announced public offering, confirming the closing of the sale of common stock and pre-funded warrants. The company successfully raised approximately $323.6 million in net proceeds, which includes the full exercise of the underwriters' option for additional shares. This substantial capital infusion significantly strengthens IDEAYA's financial position, providing crucial funding to advance its clinical development programs, particularly following recent positive trial results and new collaborations.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDYA was trading at $27.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $20.50 to $39.28. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.